Clofoctol

Clofoctol

Clinical data
AHFS/Drugs.com	International Drug Names
Routes of administration	Rectal (suppository)[1]
ATC code	J01XX03 (WHO)
Pharmacokinetic data
Bioavailability	98%[1]
Metabolism	Hepatic glucuronidation[1]
Excretion	Biliary[1]
Identifiers
IUPAC name 2-[(2,4-dichlorophenyl)methyl]- 4-(2,4,4-trimethylpentan-2-yl)phenol
CAS Number	37693-01-9
PubChem (CID)	2799
ChemSpider	2697
UNII	704083NI0R
KEGG	D07244
ChEMBL	CHEMBL1476605
ECHA InfoCard	100.048.739
Chemical and physical data
Formula	C21H26Cl2O
Molar mass	365.336 g/mol
3D model (Jmol)	Interactive image
SMILES Clc1cc(Cl)ccc1Cc2cc(ccc2O)C(C)(C)CC(C)(C)C
InChI InChI=1S/C21H26Cl2O/c1-20(2,3)13-21(4,5)16-7-9-19(24)15(11-16)10-14-6-8-17(22)12-18(14)23/h6-9,11-12,24H,10,13H2,1-5H3 Key:HQVZOORKDNCGCK-UHFFFAOYSA-N
(verify)

Clofoctol is a bacteriostatic antibiotic. It is used in the treatment of respiratory tract and ear, nose and throat infections caused by Gram-positive bacteria.^[1] It is marketed in France under the trade name Octoplus and in Italy as Gramplus.

It is only functional against Gram-positive bacteria.^[2]

It penetrates into human lung tissue.^[3]

References

1. "Gramplus" (in Italian). Studio Medico Torrino. July 25, 2007. Retrieved 2007-08-10.
2. Combe J, Simonnet F, Yablonsky F, Simonnet G (1980). "[Clofoctol binding by the bacteria (author's transl)]". J Pharmacol (in French). 11 (4): 411–25. PMID 6782374.
3. Danesi R, Gasperini M, Senesi S, Freer G, Angeletti CA, Del Tacca M (1988). "A pharmacokinetic study of clofoctol in human plasma and lung tissue by using a microbiological assay". Drugs Exp Clin Res. 14 (1): 39–43. PMID 3391105.